BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2812968
Number of visits today
613
Number of downloads
2063811
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Maccallini C, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Amoroso R. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals 2022;15:667. [DOI: 10.3390/ph15060667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sixto-López Y, Ordaz-Pichardo C, Gómez-Vidal JA, Rosales-Hernández MC, Correa-Basurto J. Cytotoxic evaluation of YSL-109 in a triple negative breast cancer cell line and toxicological evaluations. Naunyn Schmiedebergs Arch Pharmacol 2023. [PMID: 36694011 DOI: 10.1007/s00210-023-02396-7] [Reference Citation Analysis]
2 Reddy Manne M, Panicker RR, Ramakrishnan K, Hareendran HMK, Kumar Pal S, Kumar S, Pallepogu R, Desikan R, Sivaramakrishna A. Synthesis and Biological Evaluation of a Series of Quinoline‐Based Quinazolinones and Carbamic Anhydride Derivatives. ChemistrySelect 2023;8. [DOI: 10.1002/slct.202204508] [Reference Citation Analysis]
3 Ganai SA, Shah BA, Yatoo MA. Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. Advances in Cancer Research 2023. [DOI: 10.1016/bs.acr.2022.12.003] [Reference Citation Analysis]
4 Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opin Investig Drugs 2022;31:1203-26. [PMID: 36413823 DOI: 10.1080/13543784.2022.2151433] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345